BioSpace News Archive

Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.

RauCon has now introduced limits to the number of participants of its euroPLX and asiaPLX Pharma Partnering Conferences in order to increase their value for the individual participant.

GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as “Wuhan pneumonia”.

For the millions of people suffering from an allergy to peanuts, there is a new, first-of-its-kind treatment available. On Friday, the U.S. Food and Drug Administration approved Aimmune Therapeutics’ oral immunotherapy AR101.

The mechanisms that cause this collapse of normal tissue function is not well understood, but researchers recently identified key mechanisms behind it.

The company plans to present detailed study results from the WILLOW study at an upcoming medical meeting.

United Therapeutics announced that its Phase II/III DISTINCT trial failed to meet its primary efficacy endpoint.

The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.

GBA Group Pharma has informed its industry partners and clients on risks to their clinical trial plans caused by Brexit and is highlighting the significant business difficulties for healthcare companies running clinical trials through UK-based organisations.